Bayer may build a new production facility in Singapore to support the ground-breaking cell and gene therapies it is developing to cure Parkinson's disease.
The German multinational, one of the world's top pharmaceutical companies, told The Straits Times it is also looking to partner innovative biotechnology start-ups, including those working on mRNA-based vaccines and therapies.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you